Pfizer Files 2024 10-K Report
Ticker: PFE · Form: 10-K · Filed: 2025-02-27T00:00:00.000Z
Sentiment: neutral
Topics: 10-K, annual-report, pharmaceuticals
TL;DR
Pfizer's 2024 10-K is in: full financial picture for the year ending Dec 31, 2024.
AI Summary
Pfizer Inc. filed its 2024 10-K report on February 27, 2025, detailing its financial performance for the fiscal year ending December 31, 2024. The company, headquartered at 66 Hudson Boulevard East, New York, NY, operates in the Pharmaceutical Preparations industry. The filing provides comprehensive financial statements, including the Consolidated Statements of Operations, and outlines key financial data and disclosures relevant to investors.
Why It Matters
This 10-K filing provides a detailed look at Pfizer's financial health and operational performance for the past fiscal year, offering crucial insights for investors and stakeholders.
Risk Assessment
Risk Level: medium — The filing is a standard annual report and does not inherently indicate new or elevated risks.
Key Numbers
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
- 135315170 — IRS Number (Company's IRS identification number)
Key Players & Entities
- Pfizer Inc. (company) — Filer of the 10-K report
- 20241231 (date) — Fiscal year end date
- 20250227 (date) — Filing date
- 66 Hudson Boulevard East, New York, NY 10001-2192 (address) — Company business and mailing address
FAQ
What is the primary business of Pfizer Inc. according to this filing?
Pfizer Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
When was this 10-K report filed with the SEC?
This 10-K report was filed on February 27, 2025.
What fiscal period does this 10-K report cover?
The report covers the fiscal year ending December 31, 2024.
Where is Pfizer Inc. headquartered?
Pfizer Inc.'s business and mailing address is 66 Hudson Boulevard East, New York, NY 10001-2192.
What is the SEC file number for this filing?
The SEC file number for this filing is 001-03619.
From the Filing
0000078003-25-000054.txt : 20250227 0000078003-25-000054.hdr.sgml : 20250227 20250227162718 ACCESSION NUMBER: 0000078003-25-000054 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 175 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250227 DATE AS OF CHANGE: 20250227 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PFIZER INC CENTRAL INDEX KEY: 0000078003 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 135315170 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-03619 FILM NUMBER: 25679434 BUSINESS ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 BUSINESS PHONE: 2127332323 MAIL ADDRESS: STREET 1: 66 HUDSON BOULEVARD EAST CITY: NEW YORK STATE: NY ZIP: 10001-2192 FORMER COMPANY: FORMER CONFORMED NAME: PFIZER CHARLES & CO INC DATE OF NAME CHANGE: 19710908 10-K 1 pfe-20241231.htm 10-K pfe-20241231 0000078003 2024 FY false P4Y Consolidated Statements of Operations Consolidated Statements of Operations Consolidated Statements of Operations http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsCurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#LongTermDebtNoncurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent http://fasb.org/us-gaap/2024#AccountsPayableCurrent 0 10 10 40 45 80 5 35 0% 10 10 20 45 70 15 35 0 5 95 100 P5Y P7Y P3Y P3Y P5Y P1Y P3Y P1Y P5Y P7Y P3Y P5Y P7Y P3Y 33 33 33 P3Y P3Y P5Y P3Y http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherAssetsNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesCurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2024#OtherNonoperatingIncomeExpense iso4217:USD xbrli:shares iso4217:USD xbrli:shares pfe:segment xbrli:pure pfe:medicine iso4217:EUR iso4217:GBP pfe:employeeStockOwnershipPlan pfe:tradingDay pfe:measure pfe:period pfe:company pfe:patent pfe:Patent pfe:complaint pfe:operatingSegment pfe:facility pfe:country pfe:treatmentCourse 0000078003 2024-01-01 2024-12-31 0000078003 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0000078003 pfe:NotesDue20271.000Member 2024-01-01 2024-12-31 0000078003 2024-06-30 0000078003 2025-02-20 0000078003 us-gaap:ProductMember 2024-01-01 2024-12-31 0000078003 us-gaap:ProductMember 2023-01-01 2023-12-31 0000078003 us-gaap:ProductMember 2022-01-01 2022-12-31 0000078003 2023-01-01 2023-12-31 0000078003 2022-01-01 2022-12-31 0000078003 us-gaap:RoyaltyMember 2024-01-01 2024-12-31 0000078003 us-gaap:RoyaltyMember 2023-01-01 2023-12-31 0000078003 us-gaap:RoyaltyMember 2022-01-01 2022-12-31 0000078003 2024-12-31 0000078003 2023-12-31 0000078003 us-gaap:CommonStockMember 2021-12-31 0000078003 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0000078003 us-gaap:TreasuryStockCommonMember 2021-12-31 0000078003 us-gaap:RetainedEarningsMember 2021-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000078003 us-gaap:ParentMember 2021-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2021-12-31 0000078003 2021-12-31 0000078003 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000078003 us-gaap:ParentMember 2022-01-01 2022-12-31 0000078003 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-12-31 0000078003 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 20